Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study
Juan Pei, Xiuhua Xu, Ruihong Huang, Xuejuan Sun, Jun Zhang, Xing Chen, Lijing Yao, Hengyuan Zhang, Leping Shao, Yinan Li · 2025
Read Efficacy and safety of low- to medium-dose telitacicept in adults with high-risk progressive IgA nephropathy: a retrospective real-world study by Juan Pei, Xiuhua Xu, Ruihong Huang, Xuejuan Sun, Jun Zhang, Xing Chen, Lijing Yao, Hengyuan Zhang, Leping Shao, Yinan Li (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12870885.txt.
Description
A kidney disease driven by immune deposits, IgA nephropathy, can march toward failure in high-risk patients. Juan Pei and co-authors reviewed eleven such adults treated at one center in 2025 with modest doses of telitacicept, a drug that calms the antibody system. Patients took the drug weekly alongside standard care and were followed for at least twenty-four weeks.
Protein leaking into urine fell by about two thirds, and kidney function rose by about a quarter over the period. Both dose levels worked, and ten of the eleven patients responded. Side effects stayed mild, mostly sore injection spots, with no serious events. The authors read the small series as encouraging for lower-dose use.
Catalog record
| CREATOR | Juan Pei, Xiuhua Xu, Ruihong Huang, Xuejuan Sun, Jun Zhang, Xing Chen, Lijing Yao, Hengyuan Zhang, Leping Shao, Yinan Li |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |